Breadcrumb AMCP.org Resource Center AMCP joins 10 other stakeholders in letter to FDA advocating for the removal of the biosimilarity statement on labeling for biosimilar products. Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page 3/18/19 AMCP joins 10 other stakeholders in letter to FDA advocating for the removal of the biosimilarity statement on labeling for biosimilar products. Biosimilars Labeling Group Letter 6-1.pdf Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page